Should You Invest in Vertex (VRTX) Based on Bullish Wall Street Views?Zacks Investment Research • 08/02/24
Vertex Pharma: Driving Growth Through Suzetrigine And Next-Gen Cystic Fibrosis TreatmentSeeking Alpha • 08/02/24
Should Investors Worry About Vertex Pharmaceuticals $3.6 Billion Q2 Loss? Not Even for a Second.The Motley Fool • 08/02/24
Vertex Pharmaceuticals (VRTX) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 08/01/24
Vertex Slumps As Guidance Hike — Featuring The Gene-Editing Launch — Fails To Erase LossesInvestors Business Daily • 08/01/24
Vertex Pharma raises annual revenue forecast on strong demand for its cystic fibrosis treatmentsReuters • 08/01/24
Vertex Announces FDA Acceptance of New Drug Application for Suzetrigine for the Treatment of Moderate-to-Severe Acute PainBusiness Wire • 07/30/24
Curious about Vertex (VRTX) Q2 Performance? Explore Wall Street Estimates for Key MetricsZacks Investment Research • 07/29/24
Here's Why Vertex Pharmaceuticals (VRTX) Gained But Lagged the Market TodayZacks Investment Research • 07/22/24
2 Historically Flawless Metrics Suggest the Stock Market Can Plunge: Here Are 3 Stocks I've Sold Ahead of What May Be a Big Move for Wall StreetThe Motley Fool • 07/21/24
The Zacks Analyst Blog ASML, SAP, Nvidia, Vertex and EssilorLuxxotticaZacks Investment Research • 07/16/24
Orum Therapeutics Announces a Global, Multi-Target License and Option Agreement with Vertex for the Use of Orum's TPD²® Technology to Develop Novel Degrader-Antibody ConjugatesBusiness Wire • 07/16/24